P7TP3 inhibits tumor development, migration, invasion and adhesion of liver cancer through the Wnt/β-catenin signaling pathway

Jing Zhao1,2 | Yun Wang1,2 | Ming Han2 | Hongping Lu2 | Xiaofan Chen2,3 | Shunai Liu2 | Xiaoxue Yuan2 | Kai Han2 | Pu Liang2 | Jun Cheng1,2,4

Abstract
The effect of hepatitis C virus p7 trans-regulated protein 3 (P7TP3) in the development of hepatocellular carcinoma (HCC) is still unknown. The present study aimed to investigate the role and mechanism of P7TP3 in HCC. P7TP3 was significantly decreased in HCC tissues when compared with corresponding liver tissues immediately around the tumor (LAT) from seven HCC patients. Fewer and smaller colonies originated from HepG2-P7TP3 cells when compared to HepG2-NC cells. Overexpression of P7TP3 in HepG2 cells significantly repressed the growth of HCC xenografts in nude mice. Furthermore, wound-healing tests, Transwell assays, Matrigel Transwell assays, adhesion assays, CCK-8 assays, flow cytometry and western blotting analysis showed that P7TP3 protein expression inhibited migration, invasion, adhesion, proliferation and cell cycle progression in HCC cell lines. Moreover, P7TP3 suppressed the activity of the Wnt/β-catenin signaling pathway, and was restored by Wnt3a, which is an activator of the Wnt/β-catenin signaling pathway. Consistently, β-catenin was highly expressed by P7TP3 silencing, and restored by XAV939, an inhibitor of the Wnt/β-catenin signaling pathway. Finally, microRNA (miR)-182-5p suppressed the expression of target gene P7TP3 by directly interacting with the 3′-UTR region. Taken together, P7TP3, the direct target gene of miR-182-5p, inhibited HCC by regulating migration, invasion, adhesion, proliferation and cell cycle progression of liver cancer cell through the Wnt/β-catenin signaling pathway. These findings provide strong evidence that P7TP3 functions as a new promising tumor suppressor in HCC.

KEYWORDS
liver cancer, miR-182-5p, P7TP3, Wnt, β-catenin signaling pathway

1 INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is one of the leading causes of cancer death worldwide. HCC is generally related to other factors such as viral- and alcohol-related liver diseases, and nonalcoholic fatty liver disease (NAFLD). Multimodal therapies are available for treatment of this heterogeneous malignancy, which includes surgical resection, radiofrequency ablation, liver transplantation, systemic therapy such as sorafenib,
cytotoxic chemotherapy, immunotherapy and oncolytic viral ther-
apy. But, unfortunately, the mechanisms of HCC development are
still poorly investigated. Therefore, there is an urgent need to gain
insights into the novel targets by elucidating the complicated molec-
ular mechanisms of HCC development.

The P7TP3 gene, also known as TMEM50B (GenBank accession
No. DQ286229), is located at 21q22.11, is 447-bp long, and encodes
a 158-residue protein. Hepatitis C virus (HCV) p7 transactivated tar-
get genes were screened and cloned using suppression subtractive
hybridization and bioinformatic techniques, and a series of p7 protein
trans-regulated target genes were identified including several
unknown genes such as P7TP3. The P7TP3 protein contains four
transmembrane-spanning domains with cytoplasmic carboxy- and
amino-terminals. Rosen et al have developed a six-gene array-based
prediction model to diagnose benign versus malignant thyroid lesions,
which includes P7TP3. However, the function and mechanism of
P7TP3 on tumor growth and development in thyroid cancer are still
unknown. Moldrich et al have indicated that P7TP3 regulates the de-
velopment of intracellular endoplasmic reticulum and Golgi apparatus
membrane protein, proving its importance in brain development. Kong
et al have identified 11 significantly enriched genes, including P7TP3,
in Down syndrome samples by identifying differently expressed genes
(DEG) and transcription factor motifs. To date, P7TP3 has rarely been
studied, except for sequencing and localization. In the present study,
P7TP3 was confirmed as the direct target gene of microRNA (miR)-
182-5p and tumor suppressor for HCC.

MicroRNA-182 emerged as a high priority micro-RNA in HCC,
and has been proven to be associated with other cancer types. miR-182 expression is significantly upregulated in HCC patients,
dysregulated during the transition of NAFLD to non-alcoholic steatohepatitis (NASH)-HCC in mice. In a chemically induced HCC mouse model, miR-182 was overexpressed. In addition, the expres-
sion of Cited2 increased liver cell proliferation, resulting in the
progression of HCC that was suppressed by miR-182-5p. In HCC,
natural killer (NK)-cell cytotoxicity against HCC was also augmented
by miR-182. More importantly, miR-182 might exert biological ef-
fects through the Wnt/β-catenin signaling pathway. For example,
upregulation of miR-182 in human osteosarcoma inhibited cancer
progression and activated the Wnt/β-catenin signaling pathway by
transferring HOXA9. miR-182-5p also contributed to HCC metas-
tasis by activating the Wnt/β-catenin signaling pathway through
FOXO3a.

Aberrant activation of the Wnt/β-catenin signaling pathway
contributes to various diseases. In the absence of Wnt, Axin-serine/ threonine glycogen synthase kinase 3β (GSK3β)-adenomatous poly-
posis coli (APC), which is the cytoplasmic destruction complex, binds
to β-catenin, and then undergoes phosphorylation. Phosphorylated
β-catenin is ubiquitinated by β-TrCP and is then degraded by the
proteasome. Wnt induces the binding of axin and low-density li-
poprotein receptor-related protein, which destroys the degradation
complex and stabilizes β-catenin. β-Catenin then accumulates in the
cytoplasm and enters the nucleus to regulate gene transcription pro-
teins, such as cyclin D1, c-myc and MMP-7.

Based on these findings, in the present study, P7TP3 was con-
ﬁrmed as a direct target gene of miR-182-5p and as a tumor suppres-
sor in HCC, inhibiting migration, invasion, adhesion, proliferation
and cell cycle progression by downregulation of the Wnt/β-catenin
signaling pathway.

2 | MATERIALS AND METHODS

2.1 | Patients and tissues

Inclusion criteria included patients with pathologically confirmed
diagnosis of HCC. Diagnosis was made according to the guidelines
for standardized pathological diagnosis of primary HCC, 2015. Seven
patients in Beijing Ditan Hospital, Capital Medical University
were enrolled in this study. Written informed consent was obtained
before sample collection. The study was approved by the Human
Ethics Committee of the Institute Research Ethics Committee of
Beijing Ditan Hospital, Capital Medical University.

2.2 | Animal model

Animal experiments were approved by the Institute of Research Ethics
Committee of Beijing Ditan Hospital. Mice were maintained in
the Institute of Zoology, Chinese Academy of Sciences, in a specific path-
gen-free environment. Male nude mice were purchased from Beijing
Vital River Laboratory Animal Technology Company, Beijing, China.
The nude mice (weighing approximately 18-20 g and aged 6 weeks)
were randomly divided into HepG2-NC and HepG2-P7TP3 groups.
The left upper armpit of the mice in the HepG2-P7TP3 group was s.c.
jected with 0.1 mL of 1 × 10^7/mL cell suspension. Tumor size was
continuously observed and measured with a Vernier caliper. Tumor
volume was calculated by the formula: V = (length × width ×2)/2.

2.3 | Cell culture and cell treatment

HepG2 cells transfected with lentivirus for overexpression of P7TP3
(HepG2-P7TP3) or its negative control (HepG2-NC) were purchased
from Generay Biotech. HepG2 cells and HuH7 cells were stored in
our laboratory. The cells were cultured in DMEM supplemented with
10% FBS, containing 100 U/mL penicillin G, and 100 µg/mL strep-
tomycin (SV30010; Thermo Scientific) at a constant temperature of
37°C in a humid atmosphere of 5% CO2.

2.4 | Plasmids and siRNA oligonucleotides

The CoDing Sequence (CDS) for amino acids in protein fragment
of P7TP3 was ampliﬁed by PCR using genomic DNA of LO2 cells as a tem-
plate. The ampliﬁed product was cloned into pcDNA 3.1/myc-His(−)
vector. Wild-type (WT) and mutant (MUT) pmirGLO-P7TP3 3′-UTR
vectors were constructed by Generay Biotech. The chemically synthesized miR-182-5p mimic and negative mimic control (mimic-NC) were purchased from RiboBio. The CDS fragment of P7TP3 was as follows:

```
ATGGCAGGTTCATGACGACACGAGGAGGAGTGAGAGAGAAATGCT
CTGTTGTCGAGGTTGATGTTGATGTTGATGTTGATGTTGATGTTGATGT
CCTGTTGTCGAGGAGGAGTGAGAGAGAAATGCT
```

2.5 | Western blot analysis

Protein was evaluated by 12% Bis-Tris Gel/MOPS (Invitrogen) in MOPS SDS running buffer (Thermo Fisher) for 2 hours. After transferring the protein electrophoretically for 2 hours, the gels were transferred onto the PVDF membranes (Millipore), and were incubated with 5% skimmed milk (2321000; Becton, Dickinson and Company, America) for 1.5 hours. After that, the primary antibodies (Table S1) were added and maintained at 4°C overnight followed by the addition of secondary antibodies (Zhongshan Jinqiao) for 1.5 hours. Immunoreactive bands were analyzed by BiolD software (Vilber Lourmat).

2.6 | RNA extraction and quantitative reverse transcription PCR

Total RNA was isolated by total RNA Kit (Omega) and was reverse transcribed into single-stranded cDNA (Prime Script RT reagent Kit; TaKaRa). The cDNA was then subjected to quantitative reverse transcription PCR (RT-qPCR) amplification (ABI) using gene-specific primers (Hong Xun) (Table S2).

2.7 | Proliferation assay

Cell Counting Kit-8 (CCK-8 Kit) was purchased from Dojindo. Optical density was observed at 450 nm.

2.8 | Luciferase activity assay

HepG2 cells were transiently transfected with P7TP3 3′-UTR promoter plasmids, and miR-182-5p mimics/mimic-NC or miR-182-5p inhibitor/inhibitor-NC for 24 hours. For the TOP/FOP-flash system, TOP-flash plasmids and FOP-flash plasmids (TOP-flash/

FOP-flash = 50/1) were transiently transfected into HepG2 cells for 24 hours. Renilla luciferase vector plasmids served as controls. Dual-luciferase reporter assay kit was purchased from Promega.

2.9 | Colony formation assay

Cells were generated by seeding 1 × 10^4 cells per well in ultra-low adhesion in a 4-cm cell culture dish and subsequently incubated for 10-14 days. Colonies were observed under a microscope.

2.10 | Wound-healing assay

HepG2 cells were cultured in 12-well plates and then transfected with plasmids for 24 hours. Three straight scratches were drawn in each well using a 10-µL sterile pipette tip. The old medium was then exchanged with DMEM without FBS. Marked fields were detected at 0, 24, 48 and 72 hours to assess the rate of wound healing. Differences in the migration areas were considered to be the mobility.

2.11 | Transwell migration assay and Matrigel invasion assay

Medium (100 µL) without FBS containing 1 × 10^5 cells was seeded in the upper layer of Transwell plates with an 8-µm pore membrane (Corning), whereas the bottom chambers contained 600 µL DMEM containing 20% FBS. Cells in the upper chamber that did not pass through the membrane were gently wiped with a cotton swab after 24 hours. Cells in the bottom chamber that migrated were fixed with ethanol for 20 minutes at room temperature and stained with crystal violet for 20 minutes. For Matrigel invasion assay, the upper chamber of the bottom membrane was coated with 100 µL Matrigel (1:5 dilution) for 12 hours before conduction of the above experiment.

2.12 | Flow cytometry

Cells were treated with the Annexin V-FITC/7-AAD kit (BioLegend) and then detected by FACSCalibur Flow Cytometer (BD Biosciences). DNA content was detected by 7-AAD. Data were analyzed by FlowJo 7.6.1 or ModFit LT 3.1.

2.13 | Statistical analysis

Results from at least three independent experiments were taken and are presented as mean ± standard error of mean. Data calculation was done using Student’s t test. Statistical analysis was done using SPSS 17.0 software. Differences of P < .05 were considered to be statistically significant.
3 | RESULTS

3.1 | P7TP3 was downregulated in HCC tissues when compared with liver tissues immediately around the tumor

To assess the differences of P7TP3 expression between HCC and normal liver tissues, HCC tissues and the corresponding liver tissues immediately around the tumor (LAT) from seven patients with HCC were collected. Expression of P7TP3 was assessed in the two groups by real-time quantitative PCR (Figure 1A) and western blotting (Figure 1B). Compared with LAT, the expression of P7TP3 was significantly decreased in HCC tissues, indicating its crucial role in HCC.

Owing to significant downregulation of P7TP3 in HCC tissues, P7TP3 was hypothesized to play a tumor suppressor role in liver cancer. Thus, the effects of P7TP3 on colony formation and tumor development were assessed.

3.2 | P7TP3 inhibited colony formation and tumor development

Cell lines from the subsequent trials were selected and defined the potential role of P7TP3 in liver cancer to investigate the relative expression of P7TP3 in liver cell lines (Figure S1A). As a normal liver cell line, L02 served as control. Results showed that P7TP3 was low in HepG2 cells, and so it was used for overexpression experiments (Figure S1B,C). In contrast, Huh7 cells showed high expression of P7TP3 intrinsically and were used for gene silencing experiments (Figure S1D,E). P7TP3-overexpressing HepG2 cells were generated by transfection with P7TP3-expressing lentivirus as detected by fluorescence microscopy (Figure 2A), western blotting (Figure 2B), and RT-qPCR (Figure 2C). Fewer and smaller colonies originated from HepG2-P7TP3 cells when compared to HepG2-NC cells (Figure 2D). Xenograft assay in immunodeficient nude mice with HepG2-P7TP3 cells was carried out to test the tumorigenicity of P7TP3 in vivo (Figure 2E). As shown in Figure 2F, HepG2-P7TP3 cells showed significant repression of the development of HCC xenografts in nude mice.

These results suggested that P7TP3 inhibited colony formation and tumor development. However, no metastatic nodule was observed in lungs and other organs during xenograft assay in immunodeficient nude mice. Thus, liver cancer cell lines were used to investigate whether or not P7TP3 conferred potential ability in vitro.

3.3 | P7TP3 inhibited HCC cell migration, invasion and adhesion

HepG2 cells were transiently transfected with pcDNA 3.1/myc-His(−)-P7TP3 plasmid or siRNA-NC/siRNA-P7TP3. After treatment for 24 hours, the cells were scratched with straight lines, followed by detection of cell migration using wound-healing test at 0, 24, 48 and 72 hours. Difference in the migration area was considered to show mobility, which was significantly inhibited by P7TP3 (Figure 3A). Consistently, the mobility was increased after P7TP3 silencing (Figure 3B). HepG2 cells were transiently transfected with pcDNA 3.1/myc-His(−)-P7TP3 plasmid, whereas Huh7 cells were transfected with siRNA-NC/siRNA-P7TP3. Cells were harvested with a two-chamber assay after 24 hours. The cells that migrated from the upper chambers were counted, and this was considered to be the migration rate. P7TP3 overexpression suppressed HepG2 cell migration, whereas knockdown of P7TP3 promoted Huh7 cell migration (Figure 3C). Next, the cells were harvested for a Matrigel invasion assay after 24 hours. P7TP3 overexpression cells showed a remarkable decrease in the invasive ability, whereas P7TP3 silencing cells showed a significant increase when compared with the control cells (Figure 3D). HepG2 cells infected with lentivirus overexpressing P7TP3 were subjected to cell adhesion assay. Results showed that P7TP3 significantly inhibited cell adhesion ability (Figure 3E).

Epithelial cells, with adherens junctions, desmosomes and tight junctions, form a tight line of defense. Mesenchymal cells that are loosely organized lack cell adhesion and cell polarity, enabling invasion and metastasis. Epithelial mesenchymal transition (EMT) refers to the transformation of epithelial cells to mesenchymal cells, conferring the ability of cell invasion and metastasis. Hence, total protein and RNA were obtained after transformation for 48 hours. N-cadherin, a marker of mesenchymal cells, was significantly lowered by P7TP3 at both mRNA and protein levels (Figure S2A,B). Meanwhile, E-cadherin, a marker of epithelial cells, was significantly lowered by P7TP3 silencing (Figure S2C,D). Genes related to invasion and metastasis, such as snail, vimentin and MMP-7, were upregulated followed by EMT. These results indicated that P7TP3 inhibited migration, invasion and adhesion in HCC cells.

3.4 | P7TP3 inhibited HCC proliferation and cell cycle progression

As described earlier, P7TP3 dramatically inhibited the growth of HCC xenografts in nude mice, which indicates that P7TP3 has the potential ability to regulate proliferation and progression of the cell cycle. To verify this inference, protein levels of Bcl-2 and Bax were confirmed by western blotting analysis. P7TP3 accelerated the apoptosis of HCC cells and slowed down the proliferation of HCC cells (Figure 4A). Furthermore, a similar difference in proliferation rate was also observed by CCK-8 assay (Figure 4B). P7TP3 overexpression increased the rates of apoptosis of HCC cells, which were decreased by P7TP3 silencing (Figure 4C).

Next, we examined whether P7TP3 also affected cell cycle progression, using flow cytometry. P7TP3 overexpression induced a reduction of cell population in the G2 phase, whereas P7TP3 silencing caused increased numbers of cells in the G2 phase and S phase (Figure S3). By western blotting, expression of cell cycle-related proteins was detected. Expression of cyclins A, B, D1, E and CDK2 protein levels was significantly inhibited by P7TP3 overexpression, whereas the opposite results were obtained when P7TP3 expression...
was silenced (Figure 4D). Cyclins A, D1, E and CDK2, well-known cell cycle regulators that function as G1/S cell cycle checkpoints, promoted cell entry from G1 phase into S phase (Figure 4E). Therefore, G1/S cell cycle arrest was induced by P7TP3 in HCC cells.

These results showed that P7TP3 inhibited HCC by inhibiting colony formation, tumor development and HCC cell migration, invasion, and adhesion. Next, the mechanism underlying the anti-HCC effect of P7TP3 was systematically investigated in HCC cell lines.

3.5 | P7TP3 inhibited HCC by regulating the Wnt/β-catenin signaling pathway

Several signaling pathways regulated by P7TP3 involved in cell proliferation, apoptosis, and tumorigenesis were screened (Figure S4A,B). The results confirmed that cyclin D1, a nuclear target gene of the Wnt/β-catenin signaling pathway, was simultaneously decreased or increased when P7TP3 was overexpressed or silenced (Figure 4D). Therefore, it was suggested that P7TP3 attenuated HCC through the Wnt/β-catenin signaling pathway. At rest, the degradation complex that consists of Axin2, GSK3β, kinase and APC phosphorylated β-catenin undergoes ubiquitination and then degradation by the proteasome. The nucleated β-catenin that binds to the transcription factor TCF/LEF forms a complex that initiates transcription of downstream regulatory genes. To validate this hypothesis, the expression of Wnt3a, β-catenin, GSK3β, axin2, TCF-1 and TCF-4, which was regarded as the key active molecule of the Wnt/β-catenin signaling pathway, was detected (Figure 5A,B). Meanwhile, when P7TP3 was overexpressed, cyclin D1, c-myc and MMP-7, nuclear target genes of β-catenin, were significantly decreased, indicating that P7TP3 suppressed the activity of the Wnt/β-catenin signaling pathway (Figure S5C,D).

The TOP/FOP-Flash system was used for determining β-catenin-mediated transcripational activity. The TOP-Flash plasmid was constructed by cloning the TCF/LEF-DNA binding site (AGATCAAAGGGGTAA) into the firefly luciferase reporter vector. At the same time, the system also designed a control plasmid containing a mutated TCF/LEF-DNA binding site, namely the FOP-Flash plasmid for reducing the error. Activation of Wnt/β-catenin signaling pathway was strongly inhibited by P7TP3 overexpression in HepG2 cells, and vice versa, when P7TP3 gene expression was silenced in HuH7 cells (Figure 5E).

Recombinant human Wnt3a, which is an activator of the Wnt/β-catenin signaling pathway, was added to HepG2 cells at a concentration of 10 or 100 ng/mL for 24 hours. XAV939, an inhibitor of the Wnt/β-catenin signaling pathway, was added to HepG2 cells at concentrations of 0.1, 0.5, 5 or 10 µmol/L for 24 hours. Total protein obtained underwent western blotting analysis to confirm optimal concentration. According to the expression of β-catenin, the optimal dosage of Wnt3a and XAV939 in HepG2 cells was 10 ng/mL and 10 µmol/L, respectively, and this dosage was used in subsequent experiments (Figure S5A,B). The TOP/FOP-Flash system showed that Wnt3a activated the Wnt signaling pathway, whereas XAV9 inhibited the Wnt signaling pathway activity (Figure S5C). To verify if Wnt3a and XAV939 affected the basal activity of control cells, the effects of Wnt3a and XAV939 on cell viability in L02 cells (the normal hepatocyte cell line) were examined by CCK-8 kit and annexin V-FITC/7-AAD kit (Figure S5D,E). Cells were transiently transfected with pcDNA 3.1/myc-His(-)-P7TP3 plasmid or siRNA-NC/siRNA-P7TP3 for 24 hours, followed by stimulation with or without Wnt3a or XAV939 for 24 hours. Effect of P7TP3-induced reduction of β-catenin was restored by Wnt3a (Figure S5F). Consistently, β-catenin, which was highly expressed by silencing P7TP3, was restored by XAV939 (Figure S5G).

Next, whether the Wnt/β-catenin signaling pathway affected the response of HCC cell migration, invasion and adhesion to P7TP3 were examined. Inhibition of migration, invasion and adhesion derived from HepG2-P7TP3 was eliminated by Wnt3a treatment. Also, inhibition of migration and invasion derived from HepG2-siP7TP3 versus HepG2-siNC was compared by treatment with XAV939 (Figure 6). Thus, depletion of β-catenin might compromise the development of HCC, which could be completed by P7TP3. Taken together, these data suggested that P7TP3 might be a novel target for liver cancer prevention and treatment.
MiR-182-5p directly interacted with 3′-UTR of P7TP3

To determine the molecular mechanism of P7TP3 on HCC, software online forecasting was carried out. TargetScan, micro-RNA.org, miRDB and TargetMiner all predicted that miR-182-5p potentially binds to sequence in the 3′-UTR of P7TP3. More importantly, miR-182-5p promoted HCC progression, and activated the...
Wnt/β-catenin signaling pathway via FOXO3a. According to these results, miR-182-5p inhibited HCC by targeting P7TP3 through the Wnt/β-catenin signaling pathway. To verify the hypothesis, HepG2 cells were transiently transfected with miR-182-5p mimics/mimic-NC or miR-185-5p inhibitor/inhibitor-NC. Consistent with the online prediction, this study showed a significant decrease in the expression of P7TP3 in miR-185-5p mimics or miR-185-5p inhibitor group at the protein level, but not at the mRNA level (Figure 7A,B). The pmirGLO-luciferase reporter containing either the WT or mutated (MUT) miR-182-5p binding sequences in 3′-UTR of P7TP3 were constructed (Figure 7C). Activity of firefly luciferase was significantly reduced in the WT group (Figure 7D), but no significant inhibition was observed in the MUT group (Figure 7E), whereas miR-182-5p significantly increased the activity of firefly luciferase with WT but not with mutant 3′-UTR of P7TP3 (Figure 7F,G). The results strongly indicated that P7TP3 was the direct target gene of miR-182-5p.

To determine the relationship of miR-182-5p with the Wnt signal pathway, activity of the Wnt signal pathway was detected by western blot (Figure S6A), RT-qPCR (Figure S6B) and dual-luciferase reporter assays (Figure S6C). Consistent with previous findings,15 miR-182-5p mimics significantly upregulated Wnt signaling activity, whereas miR-182-5p inhibitors dramatically inhibited it.

P7TP3 was the direct target gene of miR-182-5p, and functions as a powerful cancer suppressor by targeting the Wnt/β-catenin signaling pathway.
signaling pathway. This, in turn, inhibits tumor development, migration, invasion, proliferation, and progression of the cell cycle in HCC through c-myc, MMP-7 and cyclin D1 proteins (Figure 8).

4 | DISCUSSION

In the present study, P7TP3 was reported to be a tumor suppressor gene and a direct target gene of miR-182-5p. P7TP3 inhibited tumor development, migration, invasion, proliferation, and progression of the cell cycle in HCC. Activity of the Wnt/β-catenin signaling pathway can be downregulated by P7TP3. This study is the first to report these findings and provides new insights into the role of P7TP3 as a tumor suppressor gene in HCC.

Transmembrane protein (TMEM), a type of protein that spans biological membranes, often extends through the plasma membrane or is located on the biological membrane.23 TMEM are differentially regulated in many types of cancers and are predicted to be closely
related to cancer pathogenesis. TMEM have been partly described as tumor suppressors, and are generally downregulated in tumor tissues when compared to the corresponding tissues immediately around the tumor, such as TMEM45A\textsuperscript{24} and TMEM97.\textsuperscript{25} In contrast, few TMEM are upregulated in cancer, and these function as onco-
genesis. For example, TMEM17\textsuperscript{26} and TMEM45B\textsuperscript{27,28} are associated
with poor prognosis in cancer. However, the TMEM family involves various proteins whose functions are mostly unknown, and P7TP3 is one of them. In the present study, the role and mechanism of P7TP3 in HCC were confirmed for the first time, further enriching the research on TMEM.

P7TP3 expression was downregulated in HCC tissues when compared to that in the corresponding LAT. However, no statistical relationship between P7TP3 and HCC was observed in the network database (data not shown).

**FIGURE 6** p7 Trans-regulated protein 3 (P7TP3) expression inhibited hepatocellular carcinoma through the wnt/β-catenin signaling pathway. P7TP3 was overexpressed or knocked down in HepG2 cells and Huh7 cells, respectively. After 24 h, HepG2 cells were treated with Wnt signaling pathway activator, Wnt3a (10 ng/mL) for 24 h, while the Huh7 cells were treated with Wnt pathway inhibitor XAV939 (10 μmol/L). A, B, Wound-healing tests were conducted (100×). Migration rate was measured (n = 3). C, Transwell assays were conducted (200×). Migration rate was measured (n = 3). D, Invasion rate was measured by Matrigel Transwell assays (200×) (n = 3). E, Cell adhesion was detected using HepG2 cells transfected with adenovirus (200×) (n = 3). Results are presented as mean ± standard error of mean. *$P < .05$, **$P < .01$, ***$P < .001$

**FIGURE 7** miR-182-5p promoted hepatocellular carcinoma by regulating the expression of p7 trans-regulated protein 3 (P7TP3). HepG2 cells were transiently transfected with miR-185-5p mimics/mimic-NC or miR-185-5p inhibitor/inhibitor-NC for 48 h, respectively. A, P7TP3 protein level showed significant changes when transfected with miR-185-5p mimics or miR-185-5p inhibitor, and P7TP3 protein level was analyzed by western blotting. B, P7TP3 mRNA level was analyzed by RT-qPCR. MiR-182-5p directly interacts with 3′-UTR of P7TP3: (C) prediction of binding sequences involving miR-182-5p and seed matched in P7TP3 3′-UTR and (D, E, F and G) luciferase reporter vectors were generated by inserting the wild-type (WT) or mutant (MUT) 3′-UTR fragment of P7TP3 into pmirGLO plasmid. WT or MUT plasmids were cotransfected with miR-185-5p mimics/mimic-NC or miR-185-5p inhibitor/inhibitor-NC. After 24 h, luciferase reporter assays were carried out (n = 3). Luciferase reporter assays were carried out 24 h after transfection with WT or MUT plasmids were cotransfected with miR-185-5p mimics/mimic-NC or miR-185-5p inhibitor/inhibitor-NC (n = 3). Results are presented as mean ± standard error of mean. **$P < .01$. P7TP3 expression was downregulated in HCC tissues when compared to that in the corresponding LAT. However, no statistical relationship between P7TP3 and HCC was observed in the network database (data not shown). P7TP3 is a newly discovered gene, which has rarely been studied so far. Thus, there is little information on
P7TP3 in the database to validate our findings. However, the background of patients in the database was not the same as that in our research. Our patients were all Asians, which, in turn, might lead to inconsistencies.

Moreover, miR-182-5p is considered a potential carcinogen as well as a prognostic factor in HCC. Until now, several target genes have been scanned for miR-182-5p in HCC, such as LINC01018 and FOXO3a. We herein provided a novel target gene for miR-182-5p (Figure 7), which acts as a promising tumor suppressor. In HCC, miR-182-5p directly binds to the 3'-UTR of P7TP3 mRNA by the seed sequences (Figure 7C), and silences P7TP3 by inhibiting translation of P7TP3 mRNA (Figure 7A). However, miR-182-5p is partially matched to P7TP3 mRNA rather than fully matched to it and therefore does not degrade P7TP3 mRNA (Figure 7B).

Compared to L02, which is a normal liver cell line, the expression of endogenous P7TP3 was lowered in HepG2 cells but was higher in Huh7 cells. Therefore, gene overexpression and silencing experiments were carried out in HepG2 and Huh7 cells, respectively (Figure S1). Human liver cancer cell lines are diverse and are used for various experimental purposes. HepG2 cell line is derived from hepatoblastoma, whereas Huh7 cell line is derived from highly differentiated HCC. These experiments were conducted in two liver cancer cell lines simultaneously to confirm the data. Unfortunately, the cell adhesion ability of Huh7 cells remained weak, as it was suspended in cell culture dish after straight scratches were drawn with a 10-µL sterile pipette tip. So, wound-healing assays were done in HepG2 cells only (Figure 3A,B). Lentiviral packaging Huh7 cells silencing P7TP3 were entrusted to Generay Biotech. But, so far, the cell line has not been successfully constructed. After more than 2 months of hard work, the lentivirus has successfully been built. After the lentivirus initially infects Huh7 cells, fluorescence activity can be detected by fluorescence microscopy (Figure S7A). The morphology of Huh7 cells is also normal (Figure S7B).

Hepatocellular carcinoma is the final outcome of various chronic liver diseases such as fatty liver, and so prevention of HCC progression remains a priority. In fact, we also observed that expression of P7TP3 in the liver tissues of a CCl₄-induced liver fibrosis mouse model or in the liver tissues of a high fat diet-induced fatty liver mouse model was significantly higher than that of the control group. This indicated that P7TP3 was involved in the development of fatty liver or liver fibrosis to HCC (data not shown). Therefore, the effect of P7TP3 on fibrosis or fatty liver, the role of P7TP3 in the
development of fatty liver or liver fibrosis to HCC, and the development of new anti-HCC drugs targeting P7TP3 should be explored in future.

The following questions were unanswered by our study, requiring further exploration. First, does P7TP3 promote angiogenesis by maintaining endothelial cell survival? Second, can P7TP3 be used as an early diagnostic marker for HCC? Third, can P7TP3 be used as a novel marker for assessing the risk of HCC metastasis?

In conclusion, together, these results suggested that P7TP3 inhibited migration, invasion, adhesion, proliferation and cell cycle progression of liver cancer cells. Consequently, P7TP3 might be a potential tumor suppressor in HCC. We look forward to investigating the potent alternatives for treating liver cancer.

ACKNOWLEDGMENTS
This study was supported by the National Key Research and Development Program of China (No. 2017YFC0908100 / No. 2017YFC0908104), the Beijing Municipal Administration of Hospitals (XMLX201711), the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20151701) and the National Science and Technology Major Project (No. 2017ZX10302201-005-004 and No. 2017ZX10202202-005-008). Support was also provided by the Program of Beijing Advanced Innovation Center for Big Data-Based Precision Medicine and the Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China.

DISCLOSURE
Authors declare no conflicts of interest for this article.

ORCID
Jing Zhao https://orcid.org/0000-0001-7937-8097

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103-117.
3. Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harb Perspect Med. 2015;5:a021535.
4. Tao ML, Wang CH, Jiang G, et al. Cloning and bioinformatic analysis of new gene p7TP3 and its spliced variant transregulated by hepatitis C virus p7 protein. World Chin J Digestol. 2006;14(6):576-580. In Chinese.
5. Guo J, Cheng J, Ji D, et al. Screening and cloning of target genes transactivated by hepatitis C virus p7 protein. World Chin J Digestol. 2004;12(11):2590-2593. In Chinese.
6. Rosen J, He M, Umbricht C, et al. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery 2005;138:1050-1056; discussion 1056–1057.
7. Moldrich RX, Laine J, Visel A, et al. Transmembrane protein 50b (C21orf4), a candidate for Down syndrome neuropathotypes, encodes an intracellular membrane protein expressed in the rodent brain. Neuroscience. 2008;154:1255-1266.
8. Kong XD, Liu N, Xu XJ. Bioinformatics analysis of biomarkers and transcriptional factor motifs in Down syndrome. Braz J Med Biol Res. 2014;47:834-841.
9. Cao MQ, You AB, Zhu XD, et al. miR-182-5p-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11:12.
10. Liu HN, Wu H, Chen YJ, et al. Serum microRNA signatures and metabolomics have high diagnostic value in hepatocellular carcinoma. Oncotarget. 2017;8:108881-108884.
11. Tessitore A, Ciccirelli G, Del Vecchio F, et al. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6j mice. BMC Cancer. 2016;16:3.
12. Del Vecchio F, Gallo F, Di Marco A, et al. Bioinformatics approach to predict target genes for dysregulated microRNAs in hepatocellular carcinoma: study on a chemically-induced HCC mouse model. BMC Bioinformatics. 2015;16:408.
13. Jiang Y, Chen J, Yue C, et al. The role of miR-182-5p-5p in hepatocarcinogenesis of trichloroethylene in mice. Toxicol Sci. 2017;156:208-216.
14. Abdelrahman MM, Fawzy IO, Bassiouni AA, et al. Enhancing NK cell cytotoxicity by miR-182-5p in hepatocellular carcinoma. Hum Immunol. 2016;77:667-673.
15. Zhang ZF, Wang YJ, Fan SH, et al. MicroRNA-182 downregulates Wnt/beta-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9. Oncotarget. 2017;8:101345-101361.
16. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192-1205.
17. Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985-999.
18. Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22:9279.
19. Bai J, Wu J, Tang R, et al. Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a. Invest New Drugs. 2019;34:1860–1868.
20. Jiang X, Liu F, Wang Y, Gao J. SPARC promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells and acquisition of stem cell phenotypes. J Gastroenterol Hepatol. 2019;34:1860–1868.
21. Ma XL, Shen MN, Hu B, et al. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110beta and predicts poor prognosis. J Hematol Oncol. 2019;12:37.
22. Zhou Z, Jiang H, Tu K, et al. ANKH1D is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma. Oncol Res. 2018;29:445-452.
23. Schmit K, Michiels C. TMEM Proteins in Cancer: A Review. Front Pharmacol. 2018;9:1345.
24. Manawapat-Klopfer A, Thomsen LT, Martus P, et al. TMEM45A, SERPINB5 and p16INK4A transcript levels are predictive for development of high-grade cervical lesions. Am J Cancer Res. 2016;6:1524–1536.
25. Ding H, Gui XH, Lin XB, et al. Prognostic value of MAC30 expression in human pure squamous cell carcinomas of the lung. Asian Pac J Cancer Prev. 2016;17:2705–2710.
26. Zhao Y, Song K, Zhang Y, et al. TMEM17 promotes malignant progression of breast cancer via AKT/GSK3beta signaling. Cancer Manag Res. 2018;10:2419–2428.
27. Shen K, Yu W, Yu Y, Liu X, Cui X. Knockdown of TMEM45B inhibits cell proliferation and invasion in gastric cancer. Biomed Pharmacother. 2018;104:576–581.
28. Li Y, Guo W, Liu S, et al. Silencing transmembrane protein 45B (TMEM45B) inhibits proliferation, invasion, and tumorigenesis in osteosarcoma cells. Oncol Res. 2017;25:1021-1026.
29. Wang S, Xu M, Sun Z, Yu X, Deng Y, Chang H. LINC01018 confers a novel tumor-suppressor role in hepatocellular carcinoma through sponging microRNA-182-5p. *Am J Physiol Gastrointest Liver Physiol.* 2019;317:G116–G126.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Zhao J, Wang Y, Han M, et al. P7TP3 inhibits tumor development, migration, invasion and adhesion of liver cancer through the Wnt/β-catenin signaling pathway. *Cancer Sci.* 2020;111:994–1007. [https://doi.org/10.1111/cas.14243](https://doi.org/10.1111/cas.14243)